AUTHORS
Naval Daver, MD, Jianxiang Wang Sr, MD, PhD2, Paresh Vyas, MD, PhD3, Michael Kuhn, MD4, Amir T. Fathi, MD5, Prapti Patel, MD6, Andrew H. Wei, MBBS, PhD7, Stéphane de Botton, MD, PhD8
AFFILIATIONS
1 MD Anderson Cancer Center, Houston, Texas, United States
2 National Clinical Research Center for Blood Disease, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
3 Medical Research Council Weatherall Institute of Molecular Medicine (MRC WIMM), University of Oxford, John Radcliffe Hospital, Headington,, Oxford, United Kingdom, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
4 Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
5 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
6 Servier, Boston, Massachusetts, United States
7 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
8 Institut Gustave Roussy, Villejuif, France
ABSTRACT
Background: Patients (pts) with relapsed or refractory (R/R) acute leukemia harboring KMT2A translocations (KMT2At) or NPM1c have a poor prognosis. These genetic alterations utilize the menin-KMT2A interaction to drive oncogenic HOXA9 and MEIS1 expression, to promote leukemic proliferation and to block myeloid differentiation. In spite of the recent approval of targeted therapies, response rates, duration of response, and overall survival in these R/R AML populations remain dismal, highlighting the unmet medical need. Vicrimenib (BN104/S243249) is a potent, selective, oral menin inhibitor designed to disrupt the menin-KMT2A interaction. Preclinical models with vicrimenib have shown significant anti-tumor activity and downregulation of leukemogenic genes. Preliminary data from the phase 1 study in China (NCT06052813) demonstrated encouraging clinical activity and a manageable safety profile with no dose-limiting toxicities observed at doses up to 600 mg twice daily (bid).
Study Design and Methods: This global, multicenter, open-label, phase 1/2 study (NCT07722312) is being conducted to establish the efficacy, safety, and pharmacokinetics (PK) of vicrimenib monotherapy. The study consists of a dose optimization phase followed by a dose expansion phase. The trial will enroll adult pts (≥18 years) with R/R acute leukemia (AML, ALL, or mixed phenotype acute leukemia) harboring KMT2At, NUP98t, or NPM1c. Other key inclusion criteria include expected life expectancy >3 months, ECOG PS ≤2, and adequate organ function. WBC count must be ≤25/mm3 (hydroxyurea, steroids, or vincristine to reduce WBC count is permitted) at start of study drug. Major exclusion criteria are central nervous system leukemia, disseminated intravascular coagulation, uncontrolled or severe cardiovascular disease, or uncontrolled infection.
Pts will receive vicrimenib bid continuously in 28-day treatment cycles until they proceed to hematopoietic cell transplant (HCT), or experience disease relapse, refractory disease, death, or other discontinuation from the trial. Pts who achieve a response of MLFS or better and proceed to HCT may resume vicrimenib maintenance treatment day 30 to day 180 post- transplant if there is adequate marrow recovery and organ function, no grade 2 or great acute or chronic GVHD requiring systemic treatment, and maintained continued remission.
In the dose optimization phase, up to 80 pts total will be randomized based on the use of strong CYP3A4 inhibitors for antifungal prophylaxis to identify the specific recommended phase 2 doses (RP2D). Pts not receiving strong CYP3A4 inhibitors will be randomized to either 400 mg bid or 600 mg bid BN104, and pts receiving strong CYP3A4 inhibitors will be randomized to either 300 mg bid or 450 mg bid vicrimenib. The objective is to determine the RP2D of vicrimenib monotherapy with and without strong CYP3A4 inhibitors. The primary endpoints are the incidence and severity of adverse events and the rate of complete response + complete response with partial hematologic recovery (CR+CRh). Key secondary endpoints include overall response rate (ORR), duration of response (DOR), and vicrimenib plasma PK parameters.
The dose expansion phase (n=188) will evaluate three pivotal non-randomized cohorts for KMT2At, NUP98t, and NPM1c, with an additional cohort for up to 50 pts with these target aberrations with prior menin inhibitor exposure. Pts will be treated with the RP2D in the expansion phase. The primary endpoint is CR+CRh rate. Key secondary endpoints are ORR, time to response, DOR, event-free survival, overall survival, transfusion independence, QoL, and safety.
DISCLOSURES
Naval Daver, MD: Astellas Pharma - Research Funding; GlycoMimetics - Research Funding; SERVIER - Research Funding; Bristol-Myers Squibb - Research Funding; Trovagene - Research Funding; FATE Therapeutics - Research Funding; Immunogen - Research Funding; Trillium Therapeutics - Research Funding; Novimmune - Research Funding; Daiichi Sankyo - Research Funding; Hanmi - Research Funding; Gilead Sciences - Research Funding; Kite, a Gilead company - Research Funding; Amgen - Research Funding; Pfizer - Research Funding; Abbvie - Research Funding; Genentech - Research Funding; Micro CRISPR Pvt. Ltd - Consultancy (Includes expert testimony); SERVIER - Consultancy (Includes expert testimony); Agios - Consultancy (Includes expert testimony); Gilead Sciences - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Kite, a Gilead company - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Trillium Therapeutics - Consultancy (Includes expert testimony); Astellas Pharma - Consultancy (Includes expert testimony); Daiichi Sankyo - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Consultancy (Includes expert testimony); Stemline/Menarini - Consultancy (Includes expert testimony); Arog - Consultancy (Includes expert testimony); Immunogen - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Shattuck Labs - Consultancy (Includes expert testimony); Rigel - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony)